MTOR and angiosarcoma: Some analyses have suggested alterations in pathways downstream from vascular endothelial growth factor receptor 2 (VEGFR2) are relevant targets for angiosarcoma, focusing largely on the Phosphoinositide-3-Kinase (PI3K)/ mechanistic target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) pathways.